The first was a one-time stock option exchange program for non-Executive Committee employees, which received significant support from stockholders. The second proposal allowed for the adjournment of ...

Moderna, Inc. (MRNA) is a biotechnology firm based in Cambridge, Massachusetts, that focuses on mRNA technology to create ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing concerns about its ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

Moderna Inc. (NASDAQ: MRNA) is down 35% in 2025, making it one of the worst-performing stocks among medical stocks and the broader market. Not surprisingly, the stock is down over 80% in the last 12 ...

Moderna has struggled since COVID-19 vaccine demand has shrunk. The stock has correspondingly declined, as revenue has nosedived over the last few years. The long game is clinical trials in oncology ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report)’s stock price was down 5.2% during trading on Monday after Leerink Partners lowered their price target on the stock from $18.00 to $15.00. Leerink ...

Moderna Inc (NASDAQ:MRNA) shares are flat Wednesday morning after a nearly 5% surge on Tuesday. Here’s what investors need to know. What To Know: Tuesday’s rally was driven by the release of positive ...

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of $54.63 from October 2024. Investors who bought $1,000 worth of Moderna’s ...

Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) ...

Tim Smith has 20+ years of experience in the financial services industry, both as a writer and as a trader. Moderna shares may remain under the microscope on Tuesday after sinking to a five-year low ...